MagSense Technology Animation
October 13, 2018
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense® Systems for early
Tag: ovarian cancer
Comment on US Preventive Services Task Force Recommendation Statement, "Screening for Ovarian Cancer"
May 9, 2018
This article represents the viewpoint of management. Background The worldwide incidence of ovarian cancer is 12.6 per 100,000 women. In the year 2006, ovarian cancer
Investor Update — Corporate Presentation Visuals
October 25, 2017
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content includes overviews of MagSense®
Magnetic Relaxometry for Cancer Detection
August 31, 2017
In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be
Company Overview Presentation
June 20, 2017
Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download
Magnetic Relaxometry at the 2017 AACR Meeting
April 20, 2017
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
Magnetic Relaxometry at AACR 2017
April 7, 2017
This year’s Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year’s meeting was
Earlier Detection Means An Earlier Cure
March 3, 2017
Data from the US National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program, charted below, illustrates the critical importance of early cancer detection. Earlier diagnosis